Announcements Trials
Browse Landscape

Status

Unknown 2Available 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

tempol 2balstilimab 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1tebentafusp 1talazoparib 1sodium thiosulfate 1selinexor 1ruxolitinib 1ribociclib 1osunprotafib 1nirogacestat 1mirdametinib 1lifileucel 1leronlimab 1idecabtagene vicleucel 1gedatolisib 1ensartinib 1dodecyl maltoside 1burosumab 1brexucabtagene autoleucel 1belantamab mafodotin 1axicabtagene ciloleucel 1asciminib 1anlotinib 1TEMPOL-H 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × INDUSTRY × tempol × Clear all
NCT05491928 2022-09-01

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Matrix Biomed, Inc.

Available
Tumor-Agnostic

Neoplasm Metastasis

NCT04337099 2021-05-05

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Matrix Biomed, Inc.

Available
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡